Über Briefsteller und Formelbücher in Deutschland während des Mittelalters : Vortrag in der öffentlichen Sitzung der K. Akademie der Wissenschaften am 26. März 1861 zur Vorfeier ihres 102. Stiftungstages.

Mode of access: Internet.

Short lessons on the Irish question; or, The leaflets of the Irish Press Agency, vol. 1 (nos. 1-102) /

Mode of access: Internet.

Das hebräisch-altfranzösische Glossar der Leipziger Universitäts-Bibliothek (Ms. 102),

Mode of access: Internet.

Direct support and general support maintenance repair parts and special tools list for receiver, radio frequency, Weinschel, model VM-4A, NSN 4931-01-041-1564 and tracking oscillator, Weinschel, model VM-4A/H0-2, NSN 6695-01-102-4342.

Includes index.

Barometers, ML-102-B, ML-102-D, ML-102-E, ML-102-F, and ML-316/TM.

"November 1944."

Operator's, organizational, direct support, and general support maintenance manual : telephone terminal sets AN/TCC-73(V)1, (NSN 5805-00-134-5405), AN/TCC-73(V)2, (NSN 5805-00-134-5404), AN/TCC-73A(V)1, (NSN 5805-01-102-0185) and AN/TCC-73A(V)2, (NSN 5805-01-135-7070) in shelter, electrical equipment S-419B/TCC-73(V), (NSN 5410-01-098-2393).

"29 April 1983."

Direct support and general support maintenance repair parts and special tools lists (including depot maintenance repair parts and special tools) for radio set AN/ARC-102, (NSN 5821-00-050-8255).

Includes index.

Operator's manual : digital message device group OA-8990/P, (5820-01-102-3821).

Includes index.

Operator and organizational maintenance manual : radio set AN/ARC-102.

"27 November 1963."

Post-war economic policy and planning. Preliminary report of the Special committee on post-war economic policy and planning, pursuant to S.Res.102, a resolution creating a Special committee on post-war economic policy and planning ... [and Report[s]].

Submitted by Mr. George.

Notas de Población Vol. 43 N° 102

La edición núm. 102 de Notas de Población llega a los lectores con un diverso catálogo de temas de suma importancia en el campo de los estudios demográficos y de la población de América Latina y el Caribe. Estos temas, que se analizan a lo largo de los 12 artículos que conforman este volumen, abarcan resumidamente los censos y las proyecciones de población, el análisis de la fecundidad en relación con las características de las uniones, el derecho a la salud de las personas de edad, el envejecimiento demográfico en el Brasil, las formas de convivencia de los latinoamericanos en España, la migración uruguaya de retorno desde aquel país europeo, el proceso de urbanización en el Brasil, la segregación espacial en ciudades mineras de Chile, la movilidad laboral femenina en México, el impacto de la explotación minero-energética en Colombia, los rostros diversificados del envejecimiento en el Brasil y las interrelaciones entre escolaridad, estrato social y formación de la unión en México.

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin:a randomized, double-blind, placebo-controlled 102-week trial

Background: Management of type 2 diabetes with metformin often does not provide adequate glycemic control, thereby necessitating add-on treatment. In a 24-week clinical trial, dapagliflozin, an investigational sodium glucose cotransporter 2 inhibitor, improved glycemic control in patients inadequately controlled with metformin. The present study is an extension that was undertaken to evaluate dapagliflozin as long-term therapy in this population.Methods: This was a long-term extension (total 102 weeks) of a 24-week phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group trial. Patients were randomly assigned (1:1:1:1) to blinded daily treatment (placebo, or dapagliflozin 2.5 to 5, or 10 mg) plus open-label metformin (=1,500 mg). The previously published primary endpoint was change from baseline in glycated hemoglobin (HbA1c) at 24 weeks. This paper reports the follow-up to week 102, with analysis of covariance model performed at 24 weeks with last observation carried forward; a repeated measures analysis was utilized to evaluate changes from baseline in HbA1c, fasting plasma glucose (FPG), and weight.Results: A total of 546 patients were randomized to 1 of the 4 treatments. The completion rate for the 78-week double-blind extension period was lower for the placebo group (63.5%) than for the dapagliflozin groups (68.3% to 79.8%). At week 102, mean changes from baseline HbA1c (8.06%) were +0.02% for placebo compared with -0.48% (P = 0.0008), -0.58% (P

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes:a randomized double-blind placebo-controlled 102-week trial

Aims: To assess initial pharmacotherapy of Type 2 diabetes with the sodium-glucose cotransporter-2 inhibitor dapagliflozin. Methods: This double-blind, placebo-controlled trial, randomly allocated people with Type 2 diabetes aged 18-77 years and inadequate glycaemic control on diet and exercise [HbA1c 53-86 mmol/mol (7.0-10.0%)] to receive placebo (n = 75) or dapagliflozin monotherapy 2.5 mg (n = 65), 5 mg (n = 64) or 10 mg (n = 70) once daily in the morning. After 24 weeks, low-dose double-blind metformin 500 mg/day was added to the placebo group regimen (placebo+low-dose metformin group). Changes in HbA1c level, fasting plasma glucose and body weight, as well as adverse events, were assessed over 102 weeks. Results: Of the 274 participants randomized, 167 completed the study (60.9%). At 102 weeks, significant differences vs placebo+low-dose metformin with dapagliflozin 5 and 10 mg were observed for HbA1c (-5.8 mmol/mol [-0.53%], P = 0.018; and -4.8 mmol/mol [-0.44%], P = 0.048), respectively); and for FPG (-0.69 mmol/L, P = 0.044; and -1.12 mmol/l, P = 0.001, respectively). For body weight, the difference between the dapagliflozin 10-mg group and the placebo+low-dose metformin group was significant (-2.60 kg; P = 0.016). Hypoglycaemic events were uncommon, with rates of 5.3% for placebo+low-dose metformin group and 0-4.6% for the dapagliflozin groups. Genital infections and urinary tract infections were more common in the dapagliflozin groups than in the placebo+low-dose metformin group. Conclusions: Dapagliflozin as monotherapy in treatment-naïve people with early Type 2 diabetes improved glycaemic control and reduced weight without increasing hypoglycaemia over 102 weeks. Dapagliflozin may provide an alternative initial pharmacotherapy in such people.